Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE)

INTRODUCTION: Dupilumab was initially approved in 2017 as the first biologic therapy for atopic dermatitis (AD). We characterized adults with AD initiating dupilumab in a real-world setting in the USA/Canada. METHODS: PROSE is an ongoing, longitudinal, prospective, observational, multicenter registr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagel, Jerry, Nguyen, Tien Q., Lima, Hermenio, Jain, Neal, Pariser, David M., Hsu, Sylvia, Yosipovitch, Gil, Zhang, Haixin, Chao, Jingdong, Bansal, Shikha, Chen, Zhen, Richman, Daniel, Korotzer, Andrew, Ardeleanu, Marius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209562/
https://www.ncbi.nlm.nih.gov/pubmed/35590038
http://dx.doi.org/10.1007/s13555-022-00742-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209562/
https://www.ncbi.nlm.nih.gov/pubmed/35590038
http://dx.doi.org/10.1007/s13555-022-00742-w

Ejemplares similares